Casdin Capital’s Century Therapeutics IPSC Stock Holding History

Casdin Capital’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01M	Hold	1,228,190	–	–	0.15%	35
2026 Q1	$2.78M	Hold	1,228,190	–	–	0.21%	34
2025 Q4	$1.22M	Hold	1,228,190	–	–	0.08%	35
2025 Q3	$612K	Hold	1,228,190	–	–	0.05%	30
2025 Q2	$686K	Sell	1,228,190 -1,984,126	-62%	-$1.06M	0.06%	29
2025 Q1	$1.53M	Sell	3,212,316 -1,978,190	-38%	-$1.49M	0.12%	35
2024 Q4	$5.24M	Buy	5,190,506 +1,978,190	+62%	+$2.69M	0.35%	29
2024 Q3	$5.49M	Sell	3,212,316 -1,978,190	-38%	-$3.88M	0.37%	27
2024 Q2	$13.2M	Buy	5,190,506 +1,984,126	+62%	+$6.27M	1.01%	21
2024 Q1	$13.4M	Hold	3,206,380	–	–	1%	22
2023 Q4	$10.6M	Hold	3,206,380	–	–	1.04%	20
2023 Q3	$6.41M	Hold	3,206,380	–	–	0.71%	25
2023 Q2	$10.1M	Hold	3,206,380	–	–	0.89%	24
2023 Q1	$11.1M	Hold	3,206,380	–	–	0.92%	27
2022 Q4	$16.4M	Hold	3,206,380	–	–	1.27%	23
2022 Q3	$31.7M	Hold	3,206,380	–	–	2.08%	13
2022 Q2	$26.9M	Hold	3,206,380	–	–	2.28%	13
2022 Q1	$40.4M	Hold	3,206,380	–	–	1.81%	24
2021 Q4	$50.9M	Hold	3,206,380	–	–	1.43%	25
2021 Q3	$80.7M	Hold	3,206,380	–	–	2.01%	19
2021 Q2	$94.1M	Buy	+3,206,380	New	+$81.4M	2.39%	16

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Casdin Capital's IPSC Position: Q2 2026 in Review

Casdin Capital held its Century Therapeutics (IPSC) position steady in Q2 2026 at 1,228,190 shares worth $3.01M. The position accounts for 0.15% of the portfolio, ranked #35.

Casdin Capital first reported a position in IPSC in Q2 2021 and has held it in 21 quarters since. The position peaked at $94.1M in Q2 2021. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Casdin Capital held 1,228,190 shares of Century Therapeutics worth $3.01M as of Q2 2026.
Casdin Capital left its Century Therapeutics share count unchanged in Q2 2026.
Century Therapeutics made up 0.15% of Casdin Capital's portfolio in Q2 2026, its #35 holding.
Casdin Capital first reported a position in Century Therapeutics in Q2 2021 and has held it in 21 quarters since.
Casdin Capital's Century Therapeutics position peaked at $94.1M in Q2 2021.
99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.